Moderna (MRNA) Total Current Liabilities (2017 - 2026)

Moderna (MRNA) has 10 years of Total Current Liabilities data on file, last reported at $2.4 billion in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $2.4 billion, up 49.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 billion (up 49.31% YoY), and the FY2025 annual result was $2.0 billion, down 9.93% from the prior year.
• Total Current Liabilities rose to $2.4 billion in Q1 2026 per MRNA's latest filing, from $2.0 billion in the prior quarter.
• Over five years, Total Current Liabilities peaked at $9.2 billion in Q1 2022 and troughed at $1.6 billion in Q2 2025.
• A 5-year average of $3.5 billion and a median of $2.4 billion in 2026 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2026: Total Current Liabilities sank 62.12% in 2023, then surged 49.31% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $4.9 billion in 2022, then plunged by 38.76% to $3.0 billion in 2023, then fell by 26.83% to $2.2 billion in 2024, then fell by 9.93% to $2.0 billion in 2025, then grew by 20.53% to $2.4 billion in 2026.
• Business Quant data shows MRNA's Total Current Liabilities at $2.4 billion in Q1 2026, $2.0 billion in Q4 2025, and $1.7 billion in Q3 2025.